Objective: HIV-1 natural viral suppressors (NVSs) demonstrate an intrinsic ability to control HIV-1 replication in the absence of antiretroviral therapy. The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control.
Introduction
We have recently described a cohort of HIV-1-infected individuals, natural viral suppressors (NVSs), who have the ability to naturally suppress HIV-1 to undetectable levels [1, 2] . Although a number of studies attempting to determine the mechanisms involved in the control of HIV-1 have been performed in similar cohorts (alternatively referred to as elite suppressors, elite controllers, natural controllers) [3] [4] [5] , little is known about the ability of these individuals to control other viral infections.
Given the shared transmission routes of both HIV and hepatitis C virus (HCV) and relatively high rates of coinfection seen in populations such as the NVS cohort, we sought to characterize HCV infection in the context of HIV-infected individuals with low HIV-1 viral loads. Specifically, we sought to determine whether these individuals had the ability to control HCV (another virus capable of causing persistent infection) and whether the presence of HCV within the NVS affected specific HIV-related parameters (CD4 cell count and HIV-1 viral load).
Methods

Study patients
The NVS cohort has been described in detail elsewhere [1, 2] . Briefly, after informed consent was obtained, NVS patients had to be confirmed HIV-1 positive by western blot and proviral DNA and have demonstrated viral loads less than 400 copies/ml for a 2-year time period without the use of antiretroviral therapy (one viral load > 400 copies/ml in a 2-year period was allowed, provided the subsequent values were < 400 copies/ml). All patients in the NVS cohort were required to have a hepatitis C antibody test performed. For those with a positive hepatitis C antibody, a follow-up PCR (quantitative or qualitative) was required.
Two race-control cohorts were created for comparison with the NVS cohort. The first control group consisted of HIV/HCV-coinfected patients and was defined by non-NVS status with a positive serology for both HIV and HCV. The second control group consisted of HCVmonoinfected patients (negative HIV, but positive HCV serology). Data for both control groups were extracted retrospectively by performing a chart review at the Baltimore Veterans Administration's Clinical Case Registry (CCR) database. The HIV/HCV cohort included all HIV-1/HCV-coinfected patients in the CCR database between 16 February 1997 and 16 February 2009 and the HCV-monoinfected group included an equal number of randomly selected HCV-monoinfected patients from the same time period in the same database.
Demographic and laboratory data collected
The following demographic data were collected: age, sex, race, date of diagnosis of HCVand/or HIV, estimated date of infection of HCV acquisition, risk factor for HCV, and history of HCV treatment. The following laboratory data were collected: HCVantibody and HCV viral load results (in the event of treatment history, pretreatment values were used for analysis), HCV genotype, hepatitis B serologies (surface Ab and Ag, core Ab, E Ab and Ag), aspartate transaminase (AST), alanine transaminase (ALT), albumin, alpha-fetoprotein (AFP), and liver biopsy results (when available). Additionally, for patients in the NVS group, CD4 cell count, CD4%, CD4/CD8 ratio, HIV-1 viral load, and HIV-1 proviral copy number were determined as described previously [1] .
Statistical analysis and definitions
'Chronic HCV infection' was defined as having a positive HCV antibody and PCR for HCV. 'Cleared HCV infection' was defined as having a positive HCVantibody, but negative PCR without the use of anti-HCV treatment. 'HCV-negative' individuals were those individuals who had a negative HCV antibody test. For data with normal distribution, Student's t-test was performed, otherwise, the Mann-Whitney test was used. Fisher's exact test was used for contingency table testing. All P values were two-tailed and considered significant if less than 0.05. All data were analyzed with GraphPad Prism software (GraphPad Software Inc., San Diego, California, USA).
Results
Comparison of hepatitis C virus clearance in the natural viral suppressor, HIV/hepatitis C virus, and hepatitis C virus cohorts Of the 47 NVSs, 30 were HCV antibody-positive and 17 were HCV antibody-negative. Seven of these 30 NVSs with positive HCV antibodies had negative HCV PCRs (minimum of two per patient were performed). Clearance rate of HCV infection was determined in 30 NVSs with positive HCV antibodies, 350 HIV/HCV individuals, and 350 individuals in the HCV cohort. The demographic information of these cohorts is given in Table 1 . NVS patients had a 23.3% (seven of 30) HCV clearance rate compared to 6.5% (23 of 350) in the HIV/ HCV-coinfected and 9.1% (32 of 350) in the HCVmonoinfected groups. These results were statistically significant (P ¼ 0.005 and P ¼ 0.024, respectively). These results were still significant when controlling for female sex in the Veterans Administration cohorts (P ¼ 0.011 and P ¼ 0.023, respectively). The above results are described in Table 2 .
Comparison of chronic hepatitis C virus in the natural viral suppressor, HIV/hepatitis C virus, and hepatitis C virus cohorts
HCV-related parameters were compared in patients from the three cohorts with chronic HCV infection (those with a positive HCV PCR). Twenty-three NVSs, 327 HIV/HCV-coinfected, and 318 HCV-monoinfected patients were compared.
Mean HCV viral loads were 1.92 Â 10 6 IU/ml for the NVSs, 2.55 Â 10 6 IU/ml for the HIV/HCV group, and 1.45 Â 10 6 IU/ml for the HCV group. For patients with detectable HCV viral load, there was no significant difference in the HCV viral load between the NVS and HIV/HCV or HCV groups (P ¼ 0.670 and P ¼ 0.075, respectively), though there was a significant difference between the HIV/HCV and HCV groups (P ¼ 0.003; Fig. 1 ).
Seven NVSs, 88 HIV/HCV patients, and 112 HCV patients had a liver biopsy. The NVSs had a median grade 2 and stage 1, the HCV/HIV group had a median grade 2 stage 2, and the HCV group a median grade 1 stage 1 liver disease. These results were only statistically significant between the HIV/HCV and HCV groups for grade (P ¼ 0.002) and stage (P ¼ 0.048). None of the NVSs had cirrhosis, whereas 9.2% of the HIV/HCVand 6.6% of the HCV patients had cirrhosis. These results were not statistically significant between any of the groups. There was no significant difference in AST, ALT, or AFP values among the three cohorts (data not shown). None of the individuals in NVS cohort had a history of treatment for HCV. HCV clearance rate with treatment was 12% (four of 33) in the HIV/HCV cohort and 17% (eight of 48) in the HCV cohort. A summary of the above is described in Table 2 .
Effect of hepatitis C virus upon HIV infection in the natural viral suppressor: CD4 cell count and HIV viral load
HIV-1-related parameters were studied within the NVS cohort, dividing the NVSs to those with chronic HCV (a positive HCV PCR) and those without chronic HCV infection (negative HCV PCR). The demographics of these two groups within the NVS cohort are shown in Table 3 . Within the entire NVS cohort, individuals without chronic HCV had a median CD4 cell count of 949 cells/ml, whereas those with chronic HCV had a median CD4 cell count of 654. The elevated CD4 cell count in the nonchronic HCV group was statistically significant (P ¼ 0.029). There was a similarly statistically significant elevation in the CD4% and a trend toward significance in the CD4/CD8 ratio in those without chronic HCV compared to the chronic HCV group (P ¼ 0.046 and P ¼ 0.062, respectively). The above results are shown in Fig. 2 . There was no correlation between HIV-1 proviral copy number and chronic HCV status (P ¼ 0.49). There was also no correlation between HIV-1 viral blips to more than 400 copies/ml in the past 2 years and chronic HCV status (P ¼ 0.41).
Discussion
HIV-1 NVS is a unique cohort of patients who are able to suppress HIV-1 viral replication to extremely low levels [1] . Although there have been some studies on HCV infection in long-term nonprogressors (none on the NVS or elite controllers), these have mostly focused on response to HCV treatment and effects of a specific HCV genotype on HIV progression [6, 7] . The goal of this study was to characterize HCV infection in the NVS cohort, a cohort of patients all of whom have already demonstrated the ability to control one chronic viral infection.
Our results indicate that the NVSs, as a group, demonstrate better control of HCV infection than the controls in that they had significantly higher rates of spontaneous clearance compared to race-matched historical controls of both HIV/HCV-coinfected and HCV-monoinfected patients. Spontaneous HCV clearance rates in various studies range from 6 to 80%, with a calculated mean of 26% [8] [9] [10] [11] [12] . In African-Americans, another Baltimore-based cohort with a male preponderance, a 9.3% clearance rate was reported [13] , which is similar to the clearance rate of 9.1% in our HCVmonoinfected cohort. The NVS cohort is composed of patients with variables traditionally associated with lower rates of spontaneous clearance of HCV, that is, male sex, African-American race, intravenous drug use, and HIV infection [14] . Despite this, the rate of HCV clearance in the NVS cohort was 23.3%, significantly higher than those in both the HIV/HCV-coinfected (6.5%) and HCV-monoinfected cohorts (9.1%). Recently, IL28B polymorphisms have been shown to be associated with clearance of HCV, and it remains to be seen whether this could be a potential mechanism involved in the elevated HCV clearance in the NVS group [15] . Nevertheless, the ability of some NVSs to successfully control two agents of chronic viral illness (HIV-1 and HCV) implies that a common genetic factor (controlling either innate or adaptive immunity) is responsible for the viral control in these individuals.
The only dissimilarity in the demographics of the three cohorts was male/female ratio (over-representation in the NVS compared to the other two cohorts). This is a potentially important confounder as studies have shown significantly higher clearance of HCV in women compared to men [8] [9] [10] [11] [12] . However, when controlling for female sex, the finding of a higher clearance rate in the NVS was still statistically significant when compared to the HIV/HCV and HCV groups.
Apart from the difference in HCV clearance rates, we were unable to detect any differences in HCV infection between NVSs and the controls. Those NVSs who developed chronic HCV infection did not control the infection better than the control groups, nor did they have less disease progression than the controls. The results demonstrated a difference between the HCV-monoinfected and HIV/ HCV-coinfected cohorts in terms of HCV viral load and severity of liver disease by biopsy, with the NVSs having values between those of the two groups. Although none of the results comparing the NVSs to the other groups were significant, the trend implies that the NVSs may have slightly less control of the HCV infection than the HCVmonoinfected group. These findings tend to agree with previous studies that have shown increase in HCV viral loads and HCV-related disease in HIV/HCV-coinfected patients [16] [17] [18] [19] [20] [21] [22] [23] , which is presumably because of a decrease in HCV-specific CD4 þ and CD8 þ cell response in coinfected patients [24] .
Within the NVS cohort, there was a significant association between chronic HCV infection and immunological impairment. The CD4 cell count, CD4%, and CD4/CD8 ratios were lower in those with circulating HCV than those without. The median CD4 cell difference was 294 cells/ml (with an 11% difference in CD4%). However, it should be noted that we were unable to demonstrate a difference in the HIV-1 proviral copy numbers or frequency of viral 'blips' between those NVSs with and without chronic HCV. Testing with HIV-1 viral load assays with a limit of detection of 1 copy/ml may help answer this question [25] .
Whether this degree of immunologic impairment associated with HCV infection in the NVS will eventually have clinical significance is unknown; however, these findings add to the growing body of literature regarding the detrimental effects of HCV in patients infected with HIV. The chronic engagement of B lymphocytes by HCV in chronic infection can cause nonspecific antibody production such as cryoglobulins, but it is uncertain whether this may impact the course of HIV infection. Recently, one large study has shown HCV 1692 AIDS 2010, Vol 24 No 11 Fig. 1 . Comparison of hepatitis C viral loads in the natural viral suppressor, HIV/hepatitis C virus, and hepatitis C virus cohorts. Mean hepatitis C (HCV) viral loads were 1.92 Â 10 6 IU/ml for the natural viral suppressor (NVS), 2.55 Â 10 6 IU/ml for the HIV/HCV cohort, and 1.45 Â 10 6 IU/ml for the HCV cohort. For patients with detectable HCV viral load, there was no significant difference in the HCV viral load between the NVS and HIV/HCV or HCV groups (P ¼ 0.670 and P ¼ 0.075, respectively), though there was a significant difference between the HIV/HCV and HCV groups (P ¼ 0.003). NVS cohort ¼ HIV-1-infected individuals with HIV-1 viral loads less than 400 copies/ml without therapy. HIV/HCV cohort ¼ HIV and HCV-coinfected patients. HCV cohort ¼ HCV-monoinfected patients. infection is a risk factor for developing AIDS-defining illness [26] . Previous studies have shown a blunted CD4 cell response to HAART in patients with HCV infection [16, 27] ; however, this association has not been consistently demonstrated in other studies [28] . Our study may be the first to correlate the direct impact of HCVon CD4 cell count in HIV-infected patients. Although low CD4 cell counts in HIV-negative cirrhotic patients are thought to occur secondary to splenic sequestration [29] , none of the NVSs have a clinical or pathologic diagnosis of cirrhosis. In addition, in the former case, CD4% is preserved, but the NVSs with HCV have lower CD4% and CD4/CD8 ratios, suggesting loss of CD4 rather than sequestration. The mechanism involved in the decrease in CD4 cells seen in the NVSs is likely to be an increase in naive CD4 apoptosis as has been described by Núñez et al. [30] . In typical coinfected patients, the impact of HCVon cellular immunity may be masked by the much greater HIV-induced immunosuppression; thus, cohorts such as the NVS may be more suitable for demonstrating subtle HCV-induced effects on the immune system.
Because of the inherent difficulty in identifying NVS with acute HCV, this study was cross-sectional and this The difference between the median values was 294 cells/ml. (b) A higher CD4% was noted in the NVS in the absence of chronic HCV (P ¼ 0.046). The difference between the median values was 11% points. (c) A higher CD4/CD8 ratio was noted in the NVS in the absence of chronic HCV (P ¼ 0.062). The difference between the median values was 0.68. NVS ¼ HIV-1-infected individuals with HIV-1 viral loads less than 400 copies/ml without therapy. NVS patients were divided into two groups: chronic HCVÀ (HCV PCR-negative) and chronic HCVþ (HCV PCR-positive).
has to be considered in interpreting the results. However, the NVS cohort was similarly matched to the other two cohorts, which strengthens the findings. All three cohorts were composed of African-Americans only, closely matched for age, route of infection (majority intravenous drug users), estimated date of infection for HCV, and HCV genotype (see Table 1 ). Importantly, the median estimated date of HCV infection was similar for all three cohorts (between 1973 and 1975), predating potential exposure to HIV-1. Given that our cohorts were entirely composed of African-Americans, these findings may not pertain to other ethnic groups, which can have a different genetic and immunologic makeup. Further studies are needed to confirm our findings in African-Americans and other groups of patients.
Conclusion
Individuals within the NVS cohort, who are defined based on HIV viral control, appear to clear HCV infection at an elevated rate compared to controls. NVS patients had a 23.3% clearance rate for HCV, which was significantly higher than those of HCV-monoinfected (9.1%) and HIV/HCV-coinfected (6.5%) patients. For individuals in the NVS cohort who are able to spontaneously control HIV and HCV, a common genetic factor linked to either the adaptive or innate immune system likely accounts for this finding. Within the NVS cohort, there is evidence that chronic HCV infection can have a detrimental effect on the immune system. NVS patients with chronic HCV infection had statistically significant lower CD4 cell count and CD4%. Further studies are needed to elucidate the potential mechanisms involved in HIV/HCV clearance in the NVS, as well as the immune suppressive effects of HCV within the NVS.
